Dr. Verstovsek, from The University of Texas MD Anderson Cancer Center, highlighted 3 important abstracts at the 2016 ASH annual meeting. The first study investigated overall survival data from the COMFORT-I and COMFORT-II trials of ruxolitinib to treat myelofibrosis (abstract 3110). The second looked at a Phase II study of sotatercept in myeloproliferative neoplasm–associated myelofibrosis and anemia (abstract 478). And, the third study evaluated PROUD-PV, a Phase III trial that compared
JANUARY 4, 2017